Barriers in access to oncology drugs—a global crisis
In the past decade, oncologists worldwide have seen unprecedented advances in drug
development and approvals but have also become increasingly cognizant of the rising costs …
development and approvals but have also become increasingly cognizant of the rising costs …
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study
Summary This Policy Review sourced opinions from experts in cancer care across low-
income and middle-income countries (LMICs) to build consensus around high-priority …
income and middle-income countries (LMICs) to build consensus around high-priority …
Access to and Affordability of world health organization essential medicines for cancer in sub-Saharan Africa: examples from Kenya, Rwanda, and Uganda
DA Kizub, S Naik, AA Abogan, D Pain, S Sammut… - The …, 2022 - academic.oup.com
Background Cancer mortality is high in sub-Saharan Africa (SSA), partly due to inadequate
treatment access. We explored access to and affordability of cancer treatment regimens for …
treatment access. We explored access to and affordability of cancer treatment regimens for …
Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics
Q Li, C **a, H Li, X Yan, F Yang, M Cao, S Zhang… - Frontiers of …, 2024 - Springer
Cancer is a major public health problem and represents substantial disparities worldwide.
This study reported estimates for 36 cancers across 185 countries by incidence, mortality, 5 …
This study reported estimates for 36 cancers across 185 countries by incidence, mortality, 5 …
Activities against lung cancer of biosynthesized silver nanoparticles: a review
Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat
or diagnose disease. Nanoparticles (NPs) are a special class of materials at nanometric …
or diagnose disease. Nanoparticles (NPs) are a special class of materials at nanometric …
Economic evaluation of first-line camrelizumab for advanced non-small-cell lung cancer in China
G **ang, L Gu, X Chen, F Wang, B Chen… - Frontiers in public …, 2021 - frontiersin.org
Background: As the first domestic PD-1 antibody approved for lung cancer in China,
camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) …
camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) …
Phytotherapy in integrative oncology—an update of promising treatment options
AM Zimmermann-Klemd, JK Reinhardt, M Winker… - Molecules, 2022 - mdpi.com
Modern phytotherapy is part of today's conventional evidence-based medicine and the use
of phytopharmaceuticals in integrative oncology is becoming increasingly popular …
of phytopharmaceuticals in integrative oncology is becoming increasingly popular …
Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
Q Li, C Ding, M Cao, F Yang, X Yan, S He… - Chinese Medical …, 2024 - mednexus.org
Background: Liver cancer remains the sixth most commonly diagnosed cancer and the third
leading cause of cancer-related deaths worldwide, causing a heavy burden globally. An …
leading cause of cancer-related deaths worldwide, causing a heavy burden globally. An …
National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis
Background The World Health Organization Model List of Essential Medicines (WHO EML)
has played a critical role in guiding the country-level selection and financing of medicines for …
has played a critical role in guiding the country-level selection and financing of medicines for …
Disparities in availability of new cancer drugs worldwide: 1990-2022
Introduction Despite progress in the development of new cancer drugs, concerns about
equity of access remain. This study aimed to examine the availability and timeliness of …
equity of access remain. This study aimed to examine the availability and timeliness of …